Skip to main content
Epigral Limited logo

Epigral Limited — Investor Relations & Filings

Ticker · EPIGRAL ISIN · INE071N01016 LEI · 3358008YTT28JYLL4516 BSE.NS Manufacturing
Open in API
Filings indexed 551 across all filing types
Latest filing 2024-02-26 Regulatory Filings
Country IN India
Listing BSE.NS EPIGRAL

About Epigral Limited

https://epigral.com/

Epigral Limited, formerly Meghmani Finechem Limited, operates an integrated chemical complex specializing in chlor-alkali and derivative products. The company’s core portfolio includes caustic soda, chlorine, and hydrogen, which serve as building blocks for its value-added downstream products. Key offerings include chloromethanes, hydrogen peroxide, and CPVC resin. Epigral is the first domestic producer of Epichlorohydrin (ECH), utilizing a bio-based manufacturing process. Its products are essential inputs for various applications in pharmaceuticals, textiles, water treatment, and plastics. The company focuses on expanding its specialty chemical portfolio through backward and forward integration, utilizing advanced technology to optimize production efficiency and meet the requirements of diverse global markets.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges about a scheduled one-on-one meeting with an investor (Nippon Life India Asset Management Ltd.) on February 28, 2024. It references Regulation 30 and SEBI Listing Obligations, indicating it is a regulatory disclosure. The document mentions that the latest Earnings Presentation and Corporate Presentation are already available on the company's website, but does not contain any financial data or the presentations themselves. The length is only 1668 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this document is an announcement of an investor meeting and related disclosures, fitting best under Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure.
2024-02-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice addressed to stock exchanges informing about a scheduled one-on-one virtual meeting with an investor (Guardian Capital Partners) on 26th February 2024. It references the latest Earnings Presentation and Corporate Presentation already available on the company's website but does not contain any financial data or detailed report itself. The document is an announcement of an investor meeting rather than a financial report or detailed presentation. The length is only 1648 characters, indicating it is a brief notice. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure under SEBI regulations, rather than an actual report or presentation filing.
2024-02-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about a scheduled one-on-one meeting with an investor (Vasuki India Fund) on February 23, 2024. It references Regulation 30 and SEBI Listing Obligations, indicating it is a regulatory disclosure. The document mentions that the latest Earnings Presentation and Corporate Presentation are already available on the company's website but does not contain any financial data or presentation content itself. The document length is short (1647 characters) and serves as an announcement of a meeting rather than a report or presentation. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure rather than an investor presentation or earnings release.
2024-02-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice (1660 characters) addressed to stock exchanges informing about a scheduled one-on-one meeting with an investor (Vallum Capital Advisors Pvt. Ltd.). It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The document states that the latest Earnings Presentation and Corporate Presentation are already available on the company's website and clarifies that no unpublished price sensitive information will be shared. There is no actual financial data or detailed report content in this document. It is an announcement of a meeting and related investor communication, not a financial report or presentation itself. Given the short length and nature of the content, this fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about an investor meeting and does not contain the actual presentation or report.
2024-02-16 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is a letter from Epigral Limited to stock exchanges informing about the review and reaffirmation of credit ratings by CRISIL Ratings on the company's bank facilities. It includes detailed rating information, bank-wise facility details, and disclaimers from CRISIL. The document is a regulatory announcement about credit rating updates pursuant to SEBI Listing Regulations, specifically Regulation 30, which mandates disclosure of material events. It does not contain financial statements, management discussion, or detailed financial results. It is not an annual or interim report, earnings release, or audit report. It is also not a report publication announcement since it contains substantive content about the rating review itself. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure that does not fit other specific categories.
2024-01-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on January 24, 2024, discussing the Q3 FY24 un-audited financial results of Epigral Limited. It includes detailed management commentary on financial performance, volume growth, capacity utilization, segment margins, and Q&A with investors. The text explicitly states it is a transcript of the earnings call, which is a full text record of the call including Q&A. This matches the definition of a Call Transcript (CT). The document is lengthy (15,000 characters) and contains substantive discussion of financial results and outlook, not just a brief earnings release or announcement. Therefore, the correct classification is Call Transcript (CT).
2024-01-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.